Solutions Lab and Health Care Services LLC

Solutions Lab and Health Care Services LLC was paid $1.36M by Medicaid between Nov 2021 and Sep 2024, across 60 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 50% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Missouri

Rank by total paid#15 of 61

Median peer was paid$85K

This provider vs. median16×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	1,422	$54K
2022	76,909	$932K
2023	67,923	$290K
2024incomplete	22,034	$84K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	50%	25,716	3,413	$684K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	18%	25,181	3,251	$247K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	17%	25,719	3,420	$229K
80053	Comprehensive metabolic panel	2.0%	8,063	5,214	$27K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	2.0%	10,687	6,205	$27K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.9%	2,884	1,986	$26K
84443	Thyroid stimulating hormone (TSH)	1.5%	3,977	2,737	$20K
80061	Lipid panel	1.1%	3,009	2,235	$15K
83037		<1%	3,849	2,609	$12K
80164		<1%	1,240	837	$6K
85027		<1%	3,751	2,024	$6K
80048	Basic metabolic panel (calcium, ionized)	<1%	2,335	1,386	$6K

48 more codes

82607		<1%	929	$4K
84153		<1%	495	$4K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	110	$4K
80074		<1%	241	$3K
84478		<1%	1,184	$3K
81291		<1%	110	$3K
83036	Hemoglobin; glycosylated (A1C)	<1%	715	$3K
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	<1%	2,596	$2K
36415	Collection of venous blood by venipuncture	<1%	17,293	$2K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	189	$2K
87086	Culture, bacterial; quantitative colony count, urine	<1%	891	$2K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	30	$2K
81001		<1%	1,873	$2K
82465		<1%	1,196	$2K
83718		<1%	1,185	$2K
83735		<1%	853	$2K
82728		<1%	369	$2K
80177		<1%	385	$2K
84439		<1%	752	$1K
85008		<1%	738	$832.03
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	16,611	$681.03
80076		<1%	195	$653.27
87186		<1%	138	$615.88
84481		<1%	198	$579.27
85610		<1%	572	$576.24
82652		<1%	54	$554.40
87077		<1%	130	$536.18
80178		<1%	195	$516.15
83540		<1%	298	$458.85
83880		<1%	106	$439.60
84146		<1%	33	$372.00
85046		<1%	229	$363.81
80069		<1%	160	$329.74
82140		<1%	51	$279.60
84436		<1%	202	$262.26
82570		<1%	136	$253.68
84134		<1%	55	$233.40
83550		<1%	103	$206.22
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	49	$115.56
84100		<1%	24	$48.33
82248		<1%	20	$41.11
82746		<1%	32	$35.28
86696		<1%	26	$30.96
86140		<1%	27	$28.98
81000		<1%	17	$22.47
86695		<1%	26	$21.10
86593		<1%	28	$7.04
86592		<1%	28	$6.82

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSAJJADUDDIN, MOHAMMED (OWNER)